MLN1202

DRUG5 trials

Sponsors

Millennium Pharmaceuticals, Inc., Takeda

Conditions

AtherosclerosisAtherosclerotic Cardiovascular DiseaseDiabetic NephropathyHealthy Japanese and Caucasian Male AdultsMultiple Sclerosis

Phase 1

Phase 1 Single Subcutaneous Dose Study of MLN1202

WithdrawnNCT02426021

TakedaHealthy Japanese and Caucasian Male Adults

Start: 2015-04-30End: 2015-11-30Updated: 2016-10-27

Phase 2

Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease

CompletedNCT00715169

Millennium Pharmaceuticals, Inc.Atherosclerosis

Start: 2005-08-31Updated: 2008-07-15

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

CompletedNCT01199640

Millennium Pharmaceuticals, Inc.Multiple Sclerosis

Start: 2005-05-31End: 2007-10-31Updated: 2010-09-13

Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease

WithdrawnNCT02388971

TakedaAtherosclerotic Cardiovascular Disease

Start: 2016-04-30End: 2016-04-30Updated: 2015-12-10

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

WithdrawnNCT02410499

TakedaDiabetic Nephropathy

Start: 2015-05-20End: 2015-11-17Updated: 2017-09-25